Search

Your search keyword '"MROWIETZ, Ulrich"' showing total 1,222 results
Start Over Author "MROWIETZ, Ulrich"
1,222 results on '"MROWIETZ, Ulrich"'

5. Psoriasis

Author

Mrowietz, Ulrich, Prinz, Jörg Christoph, Ruzicka, Thomas, Section editor, Plewig, Gerd, editor, French, Lars, editor, Ruzicka, Thomas, editor, Kaufmann, Roland, editor, and Hertl, Michael, editor

Published
2022
Full Text
View/download PDF

6. Papulosquamous Disorders

Author

Reich, Kristian, Mrowietz, Ulrich, Ruzicka, Thomas, Section editor, Plewig, Gerd, editor, French, Lars, editor, Ruzicka, Thomas, editor, Kaufmann, Roland, editor, and Hertl, Michael, editor

Published
2022
Full Text
View/download PDF

11. SARS‐CoV‐2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest

Author

López, María José Valencia, primary, Meineke, Anna, additional, Stephan, Brigitte, additional, Rustenbach, Stephan Jeff, additional, Kis, Anne, additional, Thaçi, Diamant, additional, Mrowietz, Ulrich, additional, Reich, Kristian, additional, Staubach‐Renz, Petra, additional, von Kiedrowski, Ralph, additional, Bogena, Henriette, additional, and Augustin, Matthias, additional

Published
2024
Full Text
View/download PDF

12. Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries

Author

Valencia López, María José, primary, Stephan, Brigitte, additional, Meineke, Anna, additional, Wolf, Sandra, additional, Thaci, Diamant, additional, Mrowietz, Ulrich, additional, Andrees, Valerie, additional, Rustenbach, Stephan, additional, Reich, Kristian, additional, Thalmann, Linus, additional, Bogena, Henriette, additional, Staubach, Petra, additional, von Kiedrowski, Ralph, additional, and Augustin, Matthias, additional

Published
2024
Full Text
View/download PDF

17. Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest.

Author

Schaeffer, Lisa, Ben-Anaya, Nesrine, Sorbe, Christina, Rustenbach, Stephan Jeff, Mrowietz, Ulrich, and Augustin, Matthias

Subjects
PSORIASIS, PSORIATIC arthritis, SURVIVAL rate, GERMANS, INTERLEUKIN-17
Abstract

Brodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and safety of brodalumab in routine care. This interim analysis of the German Psoriasis Registry PsoBest examined patient profiles, treatment outcomes, and drug survival of first-time use of brodalumab for 12months in adult patients with moderate-to-severe plaque-type psoriasis (with and without PsA) (data cutoff: June 30, 2021). Clinician and patient-reported outcomes of the total cohort (n=227; PsA, n=38) indicated a rapid response to brodalumab treatment within the first 3months, which was maintained up to 12months. The overall one-year drug survival rate was 76.2%, the mean time to discontinuation was 8.3months. Reasons for discontinuation were mainly loss/lack of effectiveness, followed by adverse events, contraindication and skin clearance. In sum, brodalumab demonstrated rapid and sustained effectiveness and was well-tolerated over 12months in German patients with moderate-to-severe psoriasis and PsA in a real-world setting. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Orismilast in moderate-to-severe psoriasis:Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS)

Author

Warren, Richard B., French, Lars E., Blauvelt, Andrew, Langley, Richard G., Egeberg, Alexander, Mrowietz, Ulrich, Hunter, Hamish J.A., Gooderham, Melinda, Soerensen, Per, Andres, Philippe, Sommer, Morten O.A., Carlsson, Anna, Kjøller, Kim D., Strober, Bruce E., Warren, Richard B., French, Lars E., Blauvelt, Andrew, Langley, Richard G., Egeberg, Alexander, Mrowietz, Ulrich, Hunter, Hamish J.A., Gooderham, Melinda, Soerensen, Per, Andres, Philippe, Sommer, Morten O.A., Carlsson, Anna, Kjøller, Kim D., and Strober, Bruce E.

Abstract

BackgroundOrismilast is a novel oral phosphodiesterase-4 (PDE4) B/D inhibitor being investigated as a potential treatment for moderate-to-severe psoriasis. ObjectiveTo evaluate efficacy and safety of orismilast modified-release formulation in moderate-to-severe psoriasis. MethodsThis multicenter, randomized (1:1:1:1 to 20, 30, 40 mg orismilast or placebo, twice daily), double-blinded, placebo-controlled, parallel-group, phase 2b, 16-week, dose-ranging study evaluated orismilast in adults with moderate-to-severe plaque psoriasis (NCT05190419). Efficacy end points were analyzed using multiple imputation. ResultsOf 202 randomized patients, baseline characteristics were balanced across arms, except greater severe disease proportions for orismilast vs placebo. Orismilast showed significant improvements in the primary end point, percentage change in Psoriasis Area and Severity Index (PASI), from baseline to week 16 (orismilast –52.6% to –63.7% and placebo, –17.3%; all P <.001). Greater proportions receiving orismilast achieved PASI75 (39.5%-49.0%; P <.05) and PASI90 (22.0%-28.3%; P <.05 for 20 and 40 mg) vs placebo (PASI75, 16.5% and PASI90, 8.3%) at week 16. Safety findings were as expected with PDE4 inhibition; dose-dependent tolerability effects observed. LimitationsSmall sample size, disease severity imbalance between groups, limited duration and diversity in study population. ConclusionOrismilast demonstrated greater efficacy vs placebo and a safety profile in line with PDE4 inhibition.

Published
2024

19. Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries

Author

Valencia López,María José, Stephan,Brigitte, Meineke,Anna, Wolf,Sandra, Thaci,Diamant, Mrowietz,Ulrich, Andrees,Valerie, Rustenbach,Stephan, Reich,Kristian, Thalmann,Linus, Bogena,Henriette, Staubach,Petra, von Kiedrowski,Ralph, Augustin,Matthias, Valencia López,María José, Stephan,Brigitte, Meineke,Anna, Wolf,Sandra, Thaci,Diamant, Mrowietz,Ulrich, Andrees,Valerie, Rustenbach,Stephan, Reich,Kristian, Thalmann,Linus, Bogena,Henriette, Staubach,Petra, von Kiedrowski,Ralph, and Augustin,Matthias

Abstract

María José Valencia López,1,&ast; Brigitte Stephan,1,&ast; Anna Meineke,1 Sandra Wolf,1 Diamant Thaci,2 Ulrich Mrowietz,3 Valerie Andrees,1 Stephan Jeff Rustenbach,1 Kristian Reich,1 Linus Thalmann,1 Henriette Bogena,1 Petra Staubach,4 Ralph Michael von Kiedrowski,5 Matthias Augustin1 1Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany; 2Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany; 3Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany; 4Department of Dermatology and Allergy, University Medical Center Mainz, Mainz, Germany; 5Dermatological Practice Selters, Selters, Germany&ast;These authors contributed equally to this workCorrespondence: Matthias Augustin, Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Martinistraße 52, Hamburg, 20246, Germany, Tel +49 040 7410 55428, Fax +49 040 7410 55348, Email m.augustin@uke.deBackground: Limited data are available characterizing the impact of the SARS-CoV-2 pandemic on psoriasis care for patients in Germany.Objective: To analyze patient perception and impact of the pandemic on well-being and psoriasis management of German patients with moderate-to-severe psoriasis or psoriasis arthritis under systemic therapies.Methods: The CoronaBest registry captures events of SARS-CoV-2 infections and analyzes the impact of the pandemic on patients with psoriasis or psoriasis arthritis. In June 2020, and independently in February 2022, patients with psoriasis or psoriasis arthritis received a standardized questionnaire for current treatment, protective measures, well-being, and individual risks for COVID-19, among others.Results: Included were 4,194 patients in 2020 (mean age of 47.7 years and 41.8% women) and 4,818 patients in 2022 (mean age of 56.4 a

Published
2024

22. SARS‐CoV‐2‐Infektionen bei Patienten mit Psoriasis in Deutschland: Daten aus den deutschen Registern PsoBest und CoronaBest.

Author

López, María José Valencia, Meineke, Anna, Stephan, Brigitte, Rustenbach, Stephan Jeff, Kis, Anne, Thaçi, Diamant, Mrowietz, Ulrich, Reich, Kristian, Staubach‐Renz, Petra, von Kiedrowski, Ralph, Bogena, Henriette, and Augustin, Matthias

Abstract

Copyright of Journal der Deutschen Dermatologischen Gesellschaft is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

23. Ixekizumab im Vergleich zu Fumarsäureestern und Methotrexat bei der Behandlung der Nagelpsoriasis bei Patienten mit mittelschwerer bis schwerer Psoriasis

Author

Augustin, Matthias, primary, Mrowietz, Ulrich, additional, Willsmann‐Theis, Dagmar, additional, Gerdes, Sascha, additional, Fotiou, Konstantinos, additional, Schuster, Christopher, additional, Mert, Can, additional, Holzkaemper, Thorsten, additional, Behrens, Frank, additional, and Pinter, Andreas, additional

Published
2024
Full Text
View/download PDF

27. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci

Author

Ellinghaus, David, Jostins, Luke, Spain, Sarah L, Cortes, Adrian, Bethune, Jörn, Han, Buhm, Park, Yu Rang, Raychaudhuri, Soumya, Pouget, Jennie G, Hübenthal, Matthias, Folseraas, Trine, Wang, Yunpeng, Esko, Tonu, Metspalu, Andres, Westra, Harm-Jan, Franke, Lude, Pers, Tune H, Weersma, Rinse K, Collij, Valerie, D'Amato, Mauro, Halfvarson, Jonas, Jensen, Anders Boeck, Lieb, Wolfgang, Degenhardt, Franziska, Forstner, Andreas J, Hofmann, Andrea, Schreiber, Stefan, Mrowietz, Ulrich, Juran, Brian D, Lazaridis, Konstantinos N, Brunak, Søren, Dale, Anders M, Trembath, Richard C, Weidinger, Stephan, Weichenthal, Michael, Ellinghaus, Eva, Elder, James T, Barker, Jonathan NWN, Andreassen, Ole A, McGovern, Dermot P, Karlsen, Tom H, Barrett, Jeffrey C, Parkes, Miles, Brown, Matthew A, and Franke, Andre

Subjects
Biological Sciences, Genetics, Prevention, 2.1 Biological and endogenous factors, Aetiology, Inflammatory and immune system, Bayes Theorem, Cholangitis, Sclerosing, Chronic Disease, Colitis, Ulcerative, Comorbidity, Crohn Disease, Genetic Heterogeneity, Genetic Pleiotropy, Genetic Variation, Genome-Wide Association Study, Genotype, Humans, Inflammation, Psoriasis, Quantitative Trait Loci, Spondylitis, Ankylosing, International IBD Genetics Consortium, International Genetics of Ankylosing Spondylitis Consortium, International PSC Study Group, Genetic Analysis of Psoriasis Consortium, Psoriasis Association Genetics Extension, Medical and Health Sciences, Developmental Biology, Agricultural biotechnology, Bioinformatics and computational biology
Abstract

We simultaneously investigated the genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis and ulcerative colitis to investigate pleiotropy and the relationship between these clinically related diseases. Using high-density genotype data from more than 86,000 individuals of European ancestry, we identified 244 independent multidisease signals, including 27 new genome-wide significant susceptibility loci and 3 unreported shared risk loci. Complex pleiotropy was supported when contrasting multidisease signals with expression data sets from human, rat and mouse together with epigenetic and expressed enhancer profiles. The comorbidities among the five immune diseases were best explained by biological pleiotropy rather than heterogeneity (a subgroup of cases genetically identical to those with another disease, possibly owing to diagnostic misclassification, molecular subtypes or excessive comorbidity). In particular, the strong comorbidity between primary sclerosing cholangitis and inflammatory bowel disease is likely the result of a unique disease, which is genetically distinct from classical inflammatory bowel disease phenotypes.

Published
2016

35. Psoriasis

Author

Mrowietz, Ulrich, Prinz, Jörg Christoph, Ruzicka, Thomas, Section editor, Plewig, Gerd, editor, Ruzicka, Thomas, editor, Kaufmann, Roland, editor, and Hertl, Michael, editor

Published
2018
Full Text
View/download PDF

38. Clinical and genetic differences between pustular psoriasis subtypes

Author

Twelves, Sophie, Mostafa, Alshimaa, Dand, Nick, Burri, Elias, Farkas, Katalin, Wilson, Rosemary, Cooper, Hywel L., Irvine, Alan D., Oon, Hazel H., Kingo, Külli, Köks, Sulev, Mrowietz, Ulrich, Puig, Luis, Reynolds, Nick, Tan, Eugene Sern-Ting, Tanew, Adrian, Torz, Kaspar, Trattner, Hannes, Valentine, Mark, Wahie, Shyamal, Warren, Richard B., Wright, Andrew, Bata-Csörgő, Zsuzsa, Szell, Marta, Griffiths, Christopher E.M., Burden, A. David, Choon, Siew-Eng, Smith, Catherine H., Barker, Jonathan N., Navarini, Alexander A., and Capon, Francesca

Published
2019
Full Text
View/download PDF

39. International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis Council

Author

Choon, Siew Eng, van de Kerkhof, Peter, Gudjonsson, Johann E., de la Cruz, Claudia, Barker, Jonathan, Morita, Akimichi, Romiti, Ricardo, Affandi, Azura Mohd, Asawanonda, Pravit, Burden, Arthur David, Gonzalez, César, Marrakchi, Slaheddine, Mowla, Mohammad Rafiqul, Okubo, Yukari, Oon, Hazel H., Terui, Tadashi, Tsai, Tsen-Fang, Callis-Duffin, Kristina, Fujita, Hideki, Jo, Seong Jin, Merola, Joseph, Mrowietz, Ulrich, Puig, Lluïs, Thaçi, Diamant, Velásquez, Margarita, Augustin, Matthias, El Sayed, Mahira, Navarini, Alexander A., Pink, Andrew, Prinz, Jörg, Turki, Hamida, Magalhães, Renata, Capon, Francesca, and Bachelez, Hervé

Abstract

IMPORTANCE: Generalized pustular psoriasis (GPP) lacks internationally accepted definitions and diagnostic criteria, impeding timely diagnosis and treatment and hindering cross-regional clinical and epidemiological study comparisons. OBJECTIVE: To develop an international consensus definition and diagnostic criteria for GPP using the modified Delphi method. EVIDENCE REVIEW: The rarity of GPP presents a challenge in acquiring comprehensive published clinical data necessary for developing standardized definition and criteria. Instead of relying on a literature search, 43 statements that comprehensively addressed the fundamental aspects of the definitions and diagnostic criteria for GPP were formulated based on expert reviews of 64 challenging GPP cases. These statements were presented to a panel of 33 global GPP experts for voting, discussion, and refinements in 2 virtual consensus meetings. Consensus during voting was defined as at least 80% agreement; the definition and diagnostic criteria were accepted by all panelists after voting and in-depth discussion. FINDINGS: In the first and second modified Delphi round, 30 (91%) and 25 (76%) experts participated. In the initial Delphi round, consensus was achieved for 53% of the statements, leading to the approval of 23 statements that were utilized to develop the proposed definitions and diagnostic criteria for GPP. During the second Delphi round, the final definition established was, “Generalized Pustular Psoriasis is a systemic inflammatory disease characterized by cutaneous erythema and macroscopically visible sterile pustules.” It can occur with or without systemic symptoms, other psoriasis types, and laboratory abnormalities. GPP may manifest as an acute form with widespread pustules or a subacute variant with an annular phenotype. The identified essential criterion was, “Macroscopically visible sterile pustules on erythematous base and not restricted to the acral region or within psoriatic plaques.” CONCLUSIONS AND RELEVANCE: The achievement of international consensus on the definition and diagnostic criteria for GPP underscores the importance of collaboration, innovative methodology, and expert engagement to address rare diseases. Although further validation is needed, these criteria can serve as a reference point for clinicians, researchers, and patients, which may contribute to more accurate diagnosis and improved management of GPP.

Published
2024
Full Text
View/download PDF

41. Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries.

Author

López, María José Valencia, Stephan, Brigitte, Meineke, Anna, Wolf, Sandra, Thaci, Diamant, Mrowietz, Ulrich, Andrees, Valerie, Rustenbach, Stephan Jeff, Reich, Kristian, Thalmann, Linus, Bogena, Henriette, Staubach, Petra, Kiedrowski, Ralph Michael von, and Augustin, Matthias

Subjects
COVID-19 pandemic, PSORIASIS, PATIENTS' attitudes, GERMANS, TERMINATION of treatment, PSORIATIC arthritis
Abstract

To analyze patient perception and impact of the pandemic on well-being and psoriasis management of German patients with moderate-to-severe psoriasis or psoriasis arthritis under systemic therapies. Methods: The CoronaBest registry captures events of SARS-CoV-2 infections and analyzes the impact of the pandemic on patients with psoriasis or psoriasis arthritis. In June 2020, and independently in February 2022, patients with psoriasis or psoriasis arthritis received a standardized questionnaire for current treatment, protective measures, well-being, and individual risks for COVID-19, among others. Results: Included were 4,194 patients in 2020 (mean age of 47.7 years and 41.8% women) and 4,818 patients in 2022 (mean age of 56.4 and 42.9% women). Treatment discontinuations were observed in 2.7% and 1.7% of patients in 2020 and 2022, respectively. In the vast majority of the cases (> 92%), no additional measures were taken concerning the management of psoriasis treatments in either 2020 or 2022. Those patients with changes reported most frequently: telephone calls instead of face-to-face visits (80.2%, in 2020 vs 40.5% in 2022) or more frequent controls (27.1%, 2020 vs 22.0%, 2022). A majority (66.7%, 2020, and 70.6%, 2022) did not perceive the virus as a considerable threat. The proportion of patients feeling well informed about COVID-19 by physicians increased from 42.6% in 2020 to 51.8% in 2022. About 81.1% of patients in 2020 and 67.5% in 2022 stated that their overall personal condition was not affected due to the pandemic. Physicians attributed no special risk of contracting SARS-CoV-2 in most of the patients. Conclusion: A high rate of systemic treatment persistence and awareness of risks and protective measures indicate that health care for psoriasis largely followed current national and international recommendations during the COVID-19 pandemic. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Charakterisierung von Patienten mit Psoriasisarthritis in der dermatologischen und rheumatologischen Versorgung: Analyse von zwei Registern

Author

Augustin, Matthias, primary, Lindner, Lisa, additional, Kühl, Laura, additional, Weiss, Anja, additional, Rustenbach, Stephan Jeff, additional, Stephan, Brigitte, additional, Feuchtenberger, Martin, additional, Mrowietz, Ulrich, additional, Thaçi, Diamant, additional, Staubach, Petra, additional, Baraliakos, Xenofon, additional, Strangfeld, Anja, additional, von Kiedrowski, Ralph, additional, Behrens, Frank, additional, and Regierer, Anne Constanze, additional

Published
2023
Full Text
View/download PDF

47. Psoriasis

Author

Mrowietz, Ulrich, primary and Prinz, Jörg Christoph, additional

Published
2020
Full Text
View/download PDF

50. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study

Author

Gasslitter, Irina, Kirsten, Natalia, Augustin, Matthias, Torz, Kaspar, Mrowietz, Ulrich, Eyerich, Kilian, Puig, Lluís, Hoetzenecker, Wolfram, Schütz-Bergmayr, Martina, Weger, Wolfgang, Wolf, Peter, Reider, Norbert, Ratzinger, Gudrun, Papageorgiou, Karolina, Meier, Thomas O., Maul, Julia-Tatjana, Anzengruber, Florian, and Navarini, Alexander A.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results